Abstract: In recent years many targeted agents treating gastric cancer have been evaluated in clinical studies. Trastuzumab, an antiHER2 monoclonal antibody, has shown activity against HER2positive gastric cancer and become the first targeted agent approved in gastric cancer. Drugs targeting epidermal growth factor receptor, including monoclonal antibody and tyrosine kinase inhibitor, bring survival benefit to patients with gastric cancer. Additionally, vascular endothelial growth factor inhibitors are also under investigation. Other targeted agents are in preclinical or early clinical development, such as mTOR inhibitors and cMET inhibitors.

Key words: Stomach neoplasms, Receptor, epidermal growth factor, Enzymeinhibitors, Targeted therapy